Related Experiment Video
Updated: Oct 5, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Rapidly Changing Serous Detachment During BRAF and MEK Inhibitor Therapy
Chisato Agata1, Kohdai Kitamoto1, Kohei Ueda1
1Department of Ophthalmology, University of Tokyo Graduate School of Medicine, Tokyo, JPN.
Abstract:
We report a case of rapidly changing serous retinal detachment (SRD) during melanoma therapy with a combination of encorafenib, a serine/threonine-protein kinase B-Raf (BRAF) inhibitor, and binimetinib, a mitogen-activated protein kinase (MEK) inhibitor. A 50-year-old woman with metastatic melanoma presented with a sudden visual blur. She had been treated with encorafenib (450 mg every morning) and binimetinib (45 mg every 12 hours) after surgery for four months. Ophthalmological examination revealed bilateral SRD, but it was completely resolved after two hours. Visual acuity was normal in each eye. Encorafenib and binimetinib were continued. Shallow SRD appeared again five months later, but it resolved in two months. MEKAR typically occurs shortly after the start of an administration, and its development after several months was very little known. Continued examination for ophthalmic events should be considered.
More Related Videos
Related Concept Videos
Cell Motility through Blebbing
Blebbing Through the Matrix
In multicellular...
MAPK Signaling Cascades
Cancer Cell Migration through Invadopodia
Intracellular Signaling Affects Focal Adhesions
Some...

